Meeting
2014 ASCO Annual Meeting
Predictive value of BRCA1 haplotype for trabectedin efficacy in patients with advanced soft-tissue sarcoma.
Authors
Audrey Laroche
Intitut Bergonié, Bordeaux, France
Audrey Laroche , Delphine Garbay , Vanessa Chaire , Valerie Le Morvan , Agnes Neuville , François Bertucci , Sébastien Salas , Roberta Sanfilippo , Philippe Pourquier , Antoine Italiano
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 10598)
DOI
10.1200/jco.2014.32.15_suppl.10598
Abstract #
10598
Poster Bd #
305
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Five-year results of a phase 2 trial using ipilimumab (I), nivolumab (N), and trabectedin (T) for previously untreated advanced soft tissue sarcoma (NCT03138161).
First Author: Erlinda Maria Gordon
Poster
2021 ASCO Annual Meeting
A randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib (2ND-STEP, JCOG1802).
First Author: Makoto Endo
Poster
2017 ASCO Annual Meeting
Trabectedin for advanced soft tissue sarcoma: Ten-year real-life perspective.
First Author: Sivan Shamai
Poster
2015 ASCO Annual Meeting
Epidemiology, treatment (tx) patterns and outcomes in Asian soft tissue sarcoma (STS) patients: Results from the Soft Tissue Sarcoma in the Asia Pacific Region (STAR) study.
First Author: Richard Hong Hui Quek